C12N 2795/14145
Special targeting system for viral vectors
C12N2795/14145 (Special targeting system for viral vectors) appears on 4 US grants and 9 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 9
- Assignees
- 8
- Inventors
- 26
- Latest grant
- 4 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 2 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- M13 phage based gene therapy platform4 Nov 2025US 12,458,674 B2Massachusetts Institute of Technology
- Phage conjugates and uses thereof5 Sep 2023US 11,744,901 B2Consiglio Nazionale Delle Ricerche
- M13 bacteriophage as a chemoaddressable nanoparticle for biological and medical applications24 Jan 2017US 9,551,666 B2University of South Carolina
- M13 bacteriophage as a chemoaddressable nanoparticle for biological and medical applications9 Apr 2013US 8,415,131 B2University of South Carolina
- Engineered phage and kit for capturing sars-cov-2 and method for detecting sars-cov-2 virus by means of said phage or kit9 Apr 2026US 2026/0098861 A1Alma Mater Studiorum - Università di Bologna
- Nucleic acid delivery system28 Aug 2025US 2025/0269056 A1
- Cancer eradicating - bio-nanoparticles (ce-bnp)2 Nov 2023US 2023/0346862 A1Athanor Biosciences, Inc.
- M13 phage based gene therapy platform9 Feb 2023US 2023/0041208 A1Massachusetts Institute of Technology
- Phage conjugates and uses thereof14 Nov 2019US 2019/0343965 A1Consiglio Nazionale Delle Ricerche
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.